CSIRO are primarily a research organisation, Bio-Gene have certainly been leveraging their scientific expertise in producing scalable Flavocide and Qcide formulations.
Larger companies have the financial capacity and influence to fast track product registration and distribution.
Licensing is the path of least resistance for BGT.
The low cash burn and healthy cash balance is one thing shareholders can’t be disappointed by.
Ann: BGT Shareholder Newsletter and Teleconference, page-18
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.859M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17584 | 3.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 26/11/2024 (20 minute delay) ? |
| BGT (ASX) Chart |
Day chart unavailable
